氯沙坦（科素亚）促尿酸排泄作用的临床研究

目的 尿酸是高血压病的危险因素之一,其主要表现为血尿酸（SUA）升高。由于高血压病人肾功能减退或肾血流量下降,故高血压患中高尿酸血症较正常血压多。高血压患中,伴有高尿酸血症心血管事件增多。在高血压病的治疗中,特异性阻断1型血管紧张素Ⅱ（AT1)受体的血管紧张素Ⅱ（ATⅡ）拮抗剂－氯沙坦（科素亚）。业已显示它是一个有效的降血压药物,且有促尿酸排泄作用。本收集了60例本院住院高血压病（1－2级）病人。随机抽取30例作治疗组,单独应用氯沙坦（科素亚）治疗。另30例作对照组。观察表明,氯沙坦（科素亚）可显促尿酸排泄,降低血尿酸水平。

Effect of losartan (COZAAR) on drainage of serum uric acid

Objective　Uric acid is one of the risk factors of hypertension, the main character is increased serum uric acid (SUA). High serum uric acid resulted in renal function letdown or descending in renal blood flow is more frequent in the patients with hypertension than those with normal blood pressure［1］. The hypertension patients associated with high serum uric acid increase the outbreaks of cardiovascular diseases. Losartan-The angiotension Ⅱ receptor blocker which is specific for angiotension Ⅱ type 1 (AT1) has been proved to be an effective antihypertensive drug. Moreover, it can increase the drainage of uric acid［2］. In the article, we collected 60 cases of hypertension in-patients(Ⅰ-Ⅱ grade), then took out 30 cases as the treated group randomly. They were treated with Losartan independently, and other 30 cases as the control group. The results suggested that Losartan increased the drainage of uric acid (P＜0.001) and reduced the serum uric acid concentration significantly(P＜0.001).